Damora Therapeutics, Inc. DMRA
22.41 USD +0.55 (+2.52%)
Nov 6, 2026, 11:15 AM EST
21.13 Day range 22.87
4.95 52-week range 38.33
- YTD
- -2.61%
- 1 year
- +285.05%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.89 +109.2% upside
Now 22.41
- Target (low)
- 40.00
- Target (mean)
- 46.89
- Target (high)
- 60.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.435 | -0.53 – -0.37 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next quarter | -0.4725 | -0.59 – -0.38 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Current year | -1.90 | -2.34 – -1.60 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next year | -2.17 | -2.59 – -1.59 | -1.90 | -14.6% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 30, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 27, 2026 | Jefferies | Initiated | — | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 12, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 11, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| May 28, 2026 | Wedbush | Initiated | — | Outperform |
| Apr 24, 2026 | RBC Capital | Initiated | — | Outperform |
| Mar 25, 2026 | Evercore ISI Group | Initiated | — | Outperform |
| Feb 17, 2026 | UBS | Initiated | — | Buy |
| Feb 17, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 7, 2026 | Leerink Partners | Initiated | — | Outperform |
| Dec 8, 2025 | Guggenheim | Maintained | Buy | Buy |
| Dec 1, 2025 | Guggenheim | Initiated | — | Buy |